Table 1.
Series demographics.
| Clinical and Pathological Parameters | Discovery Set N = 14 |
Validation Set N = 86 |
Validation Set Small-Intestine Series N = 75 |
|---|---|---|---|
| Age: median (range) | 69 (56–87) | 62 (33–87) | 62 (33–87) |
| Sex: male/female (%) | 7 (50%)/7 (50%) | 52 (61%)/34 (39%) | 47 (63%)/28 (37%) |
| Median follow–up (months) | 85 (0–198) | 73 (0–253) | 76 (0–253) |
| Median size of primary tumors (cm; range) | 11 (5–25) | 10 (4–33) | 10 (4–33) |
| Median mitotic count (/50 HPF) (range) | 13 (0–133) | 10 (0–133) | 10 (0–133) |
| Primary tumor site: | |||
| Small–intestine (%) | 14 (100%) | 75 (87%) | 75 (100%) |
| Rectum (%) | 0 (0%) | 4 (5%) | 0 (0%) |
| Colon (%) | 0 (0%) | 1 (1%) | 0 (0%) |
| Omentum (%) | 0 (0%) | 1 (1%) | 0 (0%) |
| Peritoneum | 0 (0%) | 3 (4%) | 0 (0%) |
| Others | 0 (0%) | 2 (2%) | 0 (0%) |
| Relapse: | |||
| - Yes - No |
8 (58%) 6 (42%) |
58 (67%) 28 (330%) |
49 (65%) 26 (35%) |
| Genotype: | |||
| - Wild type - KIT mutation - PDGFRA mutation - Not available |
4 (29%) 9 (64%) 1 (7%) 0 (0%) |
18 (20%) 52 (61%) 4 (5%) 12 (14%) |
17 (23%) 47 (63%) 2 (2%) 9 (12%) |
| KIT mutation: | |||
| - Exon 11 - Exon 9 - Exon 13 |
6 (67%) 2 (22%) 1 (11%) |
44 (85%) 7 (14%) 1 (1%) |
40 (85%) 6 (13%) 1 (2%) |
| Exon 11 mutation: | |||
| - Affecting codon 557/558 - Not affecting codon 557/558 |
3 (50%) 3 (50%) |
17 (39%) 27 (61%) |
17 (43%) 23 (57%) |